|
|
|
|
LEADER |
01000caa a22002652 4500 |
001 |
CTG006980163 |
003 |
DE-627 |
005 |
20230425165312.0 |
007 |
cr uuu---uuuuu |
008 |
210507s2016 xx |||||o 00| ||fin c |
035 |
|
|
|a (DE-627)CTG006980163
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)EUCTR2015-001072-22-FI
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)T51/2015
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a fin
|
245 |
1 |
0 |
|a Pegyloidun interferoni alfan teho ja turvallisuus rinovirusinfektion hoidossa.
|b Clinical and virological efficacy of pegylated interferon alpha in the treatment of rhinovirus infection in patients with primary hypogammaglobulinemia: randomized controlled trial - HypogammaInt1
|
264 |
|
1 |
|c 2016
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
500 |
|
|
|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 05-01-2016, Last updated: 2022-11-24
|
650 |
|
4 |
|a Medical Condition: Rhinovirus infection MedDRA version: 18.1Level: LLTClassification code 10039107Term: Rhinovirus infection NOSSystem Organ Class: 100000004862;Therapeutic area: Diseases [C] - Virus Diseases [C02]
|
650 |
|
4 |
|a Study Type: Interventional
|
650 |
|
4 |
|a Recruitment Status: Authorised-recruitment may be ongoing or finished
|
650 |
|
4 |
|a 610
|
773 |
0 |
8 |
|i Enthalten in
|t WHO International Clinical Trials Registry Platform
|g (2016) vom: 11. Apr.
|
773 |
1 |
8 |
|g year:2016
|g day:11
|g month:04
|
856 |
4 |
0 |
|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-001072-22
|z kostenfrei
|3 Volltext
|
912 |
|
|
|a GBV_CTG
|
912 |
|
|
|a SSG-OLC-PHA
|
951 |
|
|
|a AR
|
952 |
|
|
|j 2016
|b 11
|c 04
|